Pattern Bioscience, Inc., an innovator in rapid diagnosis and antibiotic susceptibility testing (AST) for bacterial infections, has announced the completion of a US$28.7 million Series C financing. The latest funding round was led by Illumina Ventures and Omnimed Capital and includes participation from the Antimicrobial Resistance Action Fund and Daleshaw Ltd. This new round brings the company’s total funding raised to date to US$68 million.
Latham & Watkins LLP represents Pattern Bioscience in the deal with an emerging companies team led by Austin partner Scott Craig with Houston associate Cecilia Turchetti.
Where the legal industry reads first.
Enjoyed this article? Get the biggest legal industry updates, deals, appointments, insights and expert interviews in your inbox, free.
No spam. Unsubscribe anytime.From Legal Desire
Is your firm the one being cited, or the one being skipped?
We ran the test. On several everyday legal questions, software companies are answering and law firms are not. We help firms fix that, and we build the technology behind the practice.
Lawyers and firms: get featured on Legal Desire
Share your deals, lateral moves, firm news and insights with 1M+ monthly readers: founders, law firm partners, general counsel and practising lawyers across the US, UK, EU and GCC.
Get featuredSubmit a press releaseThe advising firms, the named deal team, the value and the parties, with every other announced deal by the same firms and lawyers. Open the deal record
